Taylor PN, Zhang L, Lee RWJ, Muller I, Ezra DG, Dayan CM, Kahaly GJ, Ludgate M. New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. Nat Rev Endocrinol. 2020;16(2):104–16.

Article  CAS  PubMed  Google Scholar 

Gonçalves AC, Silva LN, Gebrim EM, Monteiro ML. Quantification of orbital apex crowding for screening of dysthyroid optic neuropathy using multidetector CT. AJNR Am J Neuroradiol. 2012;33(8):1602–7.

Article  PubMed  PubMed Central  Google Scholar 

Sun R, Zhou HF, Fan XQ. Ocular surface changes in Graves’ ophthalmopathy. Int J Ophthalmol. 2021;14(4):616–21.

Article  PubMed  PubMed Central  Google Scholar 

Kim M, Chang JH, Lee NK. Quantitative analysis of extraocular muscle volume and exophthalmos reduction after radiation therapy to treat Graves’ ophthalmopathy: a pilot study. Eur J Ophthalmol. 2021;31(2):340–5.

Article  PubMed  Google Scholar 

Ma R, Cheng Y, Gan L, Zhou X, Qian J. Histopathologic study of extraocular muscles in thyroid-associated ophthalmopathy coexisting with ocular myasthenia gravis: a case report. BMC Ophthalmol. 2020;20(1):166.

Article  PubMed  PubMed Central  Google Scholar 

Zouvelou V, Potagas C, Karandreas N, Rentzos M, Papadopoulou M, Zis VP, Vassilopoulos D. Concurrent presentation of ocular myasthenia and euthyroid Graves ophthalmopathy: a diagnostic challenge. J Clin Neurosci. 2008;15(6):719–20.

Article  CAS  PubMed  Google Scholar 

Bojikian KD, Francis CE. Thyroid Eye Disease and Myasthenia Gravis. Int Ophthalmol Clin. 2019;59(3):113–24.

Article  PubMed  Google Scholar 

Gilhus NE. Myasthenia Gravis. N Engl J Med. 2016;375(26):2570–81.

Article  CAS  PubMed  Google Scholar 

Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, Gilhus NE, Illa I, Kuntz NL, Massey J, et al. International Consensus Guidance for Management of Myasthenia gravis: 2020 update. Neurology. 2021;96(3):114–22.

Article  PubMed  PubMed Central  Google Scholar 

Bartley GB. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc. 1994;92:477–588.

CAS  PubMed  PubMed Central  Google Scholar 

An R, Li Y, Yang B, Wang H, Xu Y. Rare co-occurrence of ocular myasthenia gravis and thyroid-Associated Orbitopathy (Ophthalmopathy) in an individual with hypothyroidism. Front Endocrinol (Lausanne). 2018;9:801.

Article  PubMed  Google Scholar 

Claytor B, Li Y. Challenges in diagnosing coexisting ocular myasthenia gravis and thyroid eye disease. Muscle Nerve. 2021;63(5):631–9.

Article  PubMed  Google Scholar 

Tang J, Qin C. Rare concurrent ocular myasthenia gravis and Graves’ ophthalmopathy in a man with Poland syndrome: a case report. BMC Neurol. 2020;20(1):444.

Article  PubMed  PubMed Central  Google Scholar 

Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, Marinò M, Vaidya B, Wiersinga WM. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol. 2021;185(4):G43–67.

Article  CAS  PubMed  Google Scholar 

Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14(10):1023–36.

Article  CAS  PubMed  Google Scholar 

Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, Perez-Pampin E, Romo Lopez A, Rodríguez Alvarez FM, Castillo Laguarta JM, Del Estad Cabello A, Gessa Sorroche M, España Gregori E, et al. Efficacy of Tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves Orbitopathy: a Randomized Clinical Trial. Am J Ophthalmol. 2018;195:181–90.

Article  CAS  PubMed  Google Scholar 

Maldiney T, Deschasse C, Bielefeld P. Tocilizumab for the management of corticosteroid-resistant mild to severe Graves’ Ophthalmopathy, a report of three cases. Ocul Immunol Inflamm. 2020;28(2):281–4.

Article  CAS  PubMed  Google Scholar 

Boutzios G, Chatzi S, Goules AV, Mina A, Charonis GC, Vlachoyiannopoulos PG, Tzioufas AG. Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe Graves’ orbitopathy: an observational study. Front Endocrinol (Lausanne). 2023;14:1186105.

Article  PubMed  Google Scholar 

Yang TT, Wang ZY, Fan ZX, Yuan BY, Ma L, Lu JF, Liu PJ, He Y, Liu GZ. A pilot study on Tocilizumab in Very-Late-Onset Myasthenia Gravis. J Inflamm Res. 2023;16:5835–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ruan Z, Tang Y, Gao T, Li C, Guo R, Sun C, Huang X, Li Z, Chang T. Efficacy and safety of tocilizumab in patients with refractory generalized myasthenia gravis. CNS Neurosci Ther. 2024;30(6):e14793.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sawicka-Gutaj N, Bednarczuk T, Daroszewski J, Waligórska-Stachura J, Miśkiewicz P, Sowiński J, Bolanowski M, Ruchała M. GO-QOL–disease-specific quality of life questionnaire in Graves’ orbitopathy. Endokrynol Pol. 2015;66(4):362–6.

Article  PubMed  Google Scholar 

Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37(2):141–9.

Article  PubMed  Google Scholar 

Arcellana AES, Adiao KJB, Buenaluz-Sedurante M. Dual attack: targeting the rare co-occurrence of myasthenia gravis and Graves’ disease with radioactive iodine therapy. Endocrinol Diabetes Metab Case Rep. 2021; 2021.

Kupersmith MJ, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol. 2003;60(2):243–8.

Article  PubMed  Google Scholar 

Aricha R, Mizrachi K, Fuchs S, Souroujon MC. Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis. J Autoimmun. 2011;36(2):135–41.

Article  CAS  PubMed  Google Scholar 

Jonsson DI, Pirskanen R, Piehl F. Beneficial effect of tocilizumab in myasthenia gravis refractory to Rituximab. Neuromuscul Disord. 2017;27(6):565–8.

Article  PubMed  Google Scholar 

Uzawa A, Akamine H, Kojima Y, Ozawa Y, Yasuda M, Onishi Y, Sawai S, Kawasaki K, Asano H, Ohyama S, et al. High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis. J Neuroimmunol. 2021;358:577634.

Article  CAS  PubMed  Google Scholar 

Uzawa A, Kuwabara S, Suzuki S, Imai T, Murai H, Ozawa Y, Yasuda M, Nagane Y, Utsugisawa K. Roles of cytokines and T cells in the pathogenesis of myasthenia gravis. Clin Exp Immunol. 2021;203(3):366–74.

Article  CAS  PubMed  Google Scholar 

Uzawa A, Kawaguchi N, Himuro K, Kanai T, Kuwabara S. Serum cytokine and chemokine profiles in patients with myasthenia gravis. Clin Exp Immunol. 2014;176(2):232–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Y, Zhang Y, Li H, Jia X, Zhang X, Xia Y, Wang Y, Fu L, Xiao C, Geng D. Increased expression of P2X7 receptor in peripheral blood mononuclear cells correlates with clinical severity and serum levels of Th17-related cytokines in patients with myasthenia gravis. Clin Neurol Neurosurg. 2017;157:88–94.

Article  PubMed  Google Scholar 

Steensberg A. The role of IL-6 in exercise-induced immune changes and metabolism. Exerc Immunol Rev. 2003;9:40–7.

PubMed  Google Scholar 

Welc SS, Clanton TL. The regulation of interleukin-6 implicates skeletal muscle as an integrative stress sensor and endocrine organ. Exp Physiol. 2013;98(2):359–71.

Article  CAS  PubMed  Google Scholar 

Tsujinaka T, Fujita J, Ebisui C, Yano M, Kominami E, Suzuki K, Tanaka K, Katsume A, Ohsugi Y, Shiozaki H, et al. Interleukin 6 receptor antibody inhibits muscle atrophy and modulates p